Rethinking the Amivantamab Experience: What the COPERNICUS Data Mean for Practice in Non-Small Cell Lung Cancer

Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy.

Proactive prophylaxis with amivantamab and lazertinib cuts rash, paronychia, and clots using daily skincare, antibiotics, and anticoagulation to keep patients on therapy.

Prophylactic anticoagulation cuts VTE in lung cancer and helps patients stay on EGFR-targeted combos longer.

How chemo-free lung cancer combos like amivantamab+lazertinib boost survival, with tips to manage rashes and stay on therapy.

First-line amivantamab+lazertinib may rewire EGFR-mutant NSCLC, curb resistance, and boost survival — plus proactive clinic management tips.